{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:53:03Z","timestamp":1793292783591,"version":"4.5.0"},"reference-count":83,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Advanced hybrid closed-loop (AHCL) automated insulin delivery systems are the most effective therapy in terms of assisting people with type 1 diabetes (T1D) to achieve glycemic targets; however, the cost can represent a barrier to uptake. In this study, a cost\u2013utility analysis of the MiniMed\u2122 780G AHCL system (MM780G) versus intermittently scanned continuous glucose monitoring (is-CGM) plus multiple daily insulin injections (MDI) in people with T1D not achieving glycemic goals was performed across six European countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Clinical input data were sourced from the ADAPT trial. Assuming a baseline HbA1c of 9.04%, HbA1c reductions of 1.54% for AHCL and 0.2% for is-CGM+MDI were modeled. The analyses were performed from a payer perspective over a time horizon of 40 years and an annual discount rate of 3% was applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Across all countries, the use of AHCL was projected to result in an incremental gain in quality-adjusted life expectancy of &gt;2 quality-adjusted life years (QALYs) versus is-CGM+MDI. Lifetime direct costs were higher with AHCL resulting in incremental cost\u2013utility ratios for AHCL versus is-CGM+MDI ranging from EUR 11,765 per QALY gained in Austria to EUR 43,963 per QALY gained in Italy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>For people with T1D managed with is-CGM+MDI not achieving glycemic targets, initiation of the MM780G system was projected to improve long-term clinical outcomes; however, due to differences in health care costs between countries, the health economic outcomes differed. In all included countries, AHCL is likely to be cost-effective relative to is-CGM+MDI for people not achieving glycemic goals with is-CGM+MDI. The ADAPT trial is registered with ClinicalTrials.gov, NCT04235504.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2023.0297","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T15:40:29Z","timestamp":1696606829000},"page":"864-876","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["A European Cost\u2013Utility Analysis of the MiniMed\u2122 780G Advanced Hybrid Closed-Loop System Versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People Living with Type 1 Diabetes"],"prefix":"10.1177","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1025-1682","authenticated-orcid":false,"given":"Johan","family":"Jendle","sequence":"first","affiliation":[{"name":"School of Medical Sciences, \u00d6rebro University, \u00d6rebro, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ida","family":"Buompensiere","sequence":"additional","affiliation":[{"name":"Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asli Zeynep","family":"Ozdemir Saltik","sequence":"additional","affiliation":[{"name":"Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"de Portu","sequence":"additional","affiliation":[{"name":"Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6049-1241","authenticated-orcid":false,"given":"Jayne","family":"Smith-Palmer","sequence":"additional","affiliation":[{"name":"Covalence Research Ltd., Harpenden, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Pollock","sequence":"additional","affiliation":[{"name":"Covalence Research Ltd., Harpenden, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4337-1795","authenticated-orcid":false,"given":"Ohad","family":"Cohen","sequence":"additional","affiliation":[{"name":"Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13588"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/1932296816650900"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00212-1"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14575"},{"key":"e_1_3_5_6_2","first-page":"339","article-title":"Barriers to uptake of insulin technologies and novel solutions","volume":"14","author":"Pauley ME","year":"2021","unstructured":"Pauley ME, , Berget C, , Messer LH, et al. Barriers to uptake of insulin technologies and novel solutions. Med Devices (Auckl), 2021; 14:339\u2013354.","journal-title":"Med Devices (Auckl)"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1536"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1188823"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X1980"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X2006"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.07.007"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S114699"},{"key":"e_1_3_5_13_2","unstructured":"National Institute of Health and Care Excellence. Type 1 diabetes in adults: Diagnosis and management Economic modelling for continuous glucose monitoring in adults with type 1 diabetes NICE guideline NG17. Economic model report; March 2022. Available from: https:\/\/www.nice.org.uk\/guidance\/ng17\/evidence\/economic-model-report-pdf-9196141213 [Last accessed: February16 2023]."},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.03.003"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X115757"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-050635"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1610"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2018.1443810"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00810-8"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer.15.38"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2023.02.006"},{"key":"e_1_3_5_22_2","first-page":"334","article-title":"What is an efficient health technology in Spain? [in Spanish]","volume":"16","author":"Sacrist\u00e1n JA","year":"2002","unstructured":"Sacrist\u00e1n JA, , Oliva J, , Del Llano J, et al. What is an efficient health technology in Spain? [in Spanish]. Gac Sanit, 2002; 16:334\u2013343.","journal-title":"Gac Sanit"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2021.0443"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01157-0"},{"issue":"2","key":"e_1_3_5_25_2","first-page":"A","article-title":"12-Month results of the ADAPT randomized controlled trial: Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes","volume":"25","author":"Van Den Heuvel T","year":"2023","unstructured":"Van Den Heuvel T, , Choudhary P, , Kolassa R, et al. 12-Month results of the ADAPT randomized controlled trial: Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes. Diabetes Technol Ther, 2023; 25(Suppl 2):A-46.","journal-title":"Diabetes Technol Ther"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-006-0360-z"},{"key":"e_1_3_5_27_2","unstructured":"AIFA. Guideline for compiling chapter 9 of the dossier. Available from: https:\/\/www.aifa.gov.it\/en\/linea-guida-capitolo-9 [Last accessed: July19 2022]."},{"key":"e_1_3_5_28_2","unstructured":"Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket. General Advice of the Dental and Pharmaceutical Benefits Agency. 2017. Available from: https:\/\/www.tlv.se\/om-oss\/om-tlv\/regelverk\/allmanna-rad.html [Last accessed: July19 2022]."},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-010-0244-4"},{"key":"e_1_3_5_30_2","unstructured":"Bundesministerium f\u00fcr Soziales Gesundheit Pflege und Konsumentenschutz. Performance-oriented Hospital Financing. Available from: https:\/\/www.sozialministerium.at\/Themen\/Gesundheit\/Gesundheitssystem\/Krankenanstalten\/Leistungsorientierte-Krankenanstaltenfinanzierung-(LKF).html [Last accessed: February19 2023]."},{"key":"e_1_3_5_31_2","unstructured":"\u00d6sterreichische Gesundheitskasse. Available from: https:\/\/www.gesundheitskasse.at\/cdscontent\/?contentid=10007.867331&portal=oegkportal [Last accessed: August 30 2023]."},{"key":"e_1_3_5_32_2","unstructured":"Insitut f\u00fcr Phama\u00f6konomishce Forschung. Available from: https:\/\/ipf-ac.at\/en\/ [Last accessed: February 19 2023]."},{"key":"e_1_3_5_33_2","unstructured":"Warenverzeichnis online des \u00d6sterreichischen Apotheker-Verlages. Available from: https:\/\/warenverzeichnis.apoverlag.at\/ [Last accessed: February 19 2023]."},{"key":"e_1_3_5_34_2","unstructured":"Statistics Austria. Available from: https:\/\/www.statistik.at\/en [Last accessed: February 19 2023]."},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-016-0410-2"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.04.030"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.12.010"},{"key":"e_1_3_5_38_2","first-page":"680","article-title":"Cost-effectiveness analysis comparing apixaban and acenocoumarol in the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain","volume":"68","author":"Bar\u00f3n Esquivias G","year":"2015","unstructured":"Bar\u00f3n Esquivias G, , Escolar Albaladejo G, , Zamorano JL, et al. Cost-effectiveness analysis comparing apixaban and acenocoumarol in the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain. Rev Esp Cardiol (Engl Ed), 2015; 68:680\u2013690.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200927010-00008"},{"key":"e_1_3_5_40_2","unstructured":"Gesundheit \u00d6sterreich. Social Security Rehabilitation Plan 2020. Available from: https:\/\/www.sozialversicherung.at\/cdscontent\/load?contentid=10008.742311&version=1611835415 [Last accessed: April12 2023]."},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs355"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000100723.50363.2C"},{"key":"e_1_3_5_43_2","first-page":"228","article-title":"Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain [in Spanish]","volume":"27","author":"Cosin Sales J","year":"2015","unstructured":"Cosin Sales J, , Fuentes Jim\u00e9nez FJ, , Mantilla Morat\u00f3 T, et al. Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain [in Spanish]. Clin Investig Arterioscler, 2015; 27:228\u2013238.","journal-title":"Clin Investig Arterioscler"},{"key":"e_1_3_5_44_2","unstructured":"Nederlands Huisartsen Genootschap. NHG Guidelines. Available from: https:\/\/www.nhg.org\/ [Last accessed: April12 2023]."},{"key":"e_1_3_5_45_2","unstructured":"Bundesministerium f\u00fcr Arbeit Soziales Gesundheit und Konsumentenschutz. Hospitals in Numbers. 2018. Available from: https:\/\/www.kaz.bmg.gv.at\/fileadmin\/user_upload\/Publikationen\/Oesterreich_2018.pdf [Last accessed: February19 2023]."},{"key":"e_1_3_5_46_2","first-page":"63","article-title":"Heart Failure in Eastern Veneto: Prevalence, Hospitalization, Adherence to Guidelines and Social Costs","volume":"66","author":"Valle R","year":"2006","unstructured":"Valle R, , Baccichetto R, , Barro S, et al. Heart Failure in Eastern Veneto: Prevalence, Hospitalization, Adherence to Guidelines and Social Costs. Monaldi Arch Chest Dis, 2006; 66:63\u201374.","journal-title":"Monaldi Arch Chest Dis"},{"key":"e_1_3_5_47_2","unstructured":"Nederlandse Zorgautoriteit. DBC Information System. 2022. Available from: https:\/\/www.opendisdata.nl\/ [Last accessed: February19 2023]."},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2013.12.016"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08614-x"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-137"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2018.11.002"},{"key":"e_1_3_5_52_2","unstructured":"Ghatnekar O Steen Carlsson K. Costs of Stroke in 2009. An Incidence-based Study. Institutet f\u00f6r h\u00e4lso- och sjukv\u00e5rdsekonomi IHE: Lund Sverige. Available from: https:\/\/ihe.se\/wp-content\/uploads\/2017\/10\/IHE-RAPPORT-2012_2_.pdf [Last accessed: April12 2023]."},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200220001-00005"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X65349"},{"key":"e_1_3_5_55_2","unstructured":"Marone E Mantovani LG Ciampichini R et al. Peripheral arterial disease in diabetics: Epidemiology and costs of a population-based study. XI Congressio Nazionale Della Societa Italiana Di Chirurgia Vascolare ed Endvascolare. Milano 4\u20136 Ottobre 2015."},{"key":"e_1_3_5_56_2","first-page":"182","article-title":"Direct cost of diabetes mellitus and its complications in Spain (SECCAID Study: Spain estimated cost Ciberdem-Cabimer in Diabetes)","volume":"29","author":"Crespo C","year":"2013","unstructured":"Crespo C, , Brosa M, , Soria-Juan A, et al. Direct cost of diabetes mellitus and its complications in Spain (SECCAID Study: Spain estimated cost Ciberdem-Cabimer in Diabetes). Adv Diabetol, 2013; 29:182\u2013189.","journal-title":"Adv Diabetol"},{"key":"e_1_3_5_57_2","unstructured":"Bundesministerium Soziales Gesundheit Pflege und Konsumentenschutz. Medical Institutions. Available from: https:\/\/www.sozialministerium.at\/Themen\/Gesundheit\/Gesundheitssystem\/Krankenanstalten\/ [Last accessed: April12 2023]."},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03320626"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.2165\/00024677-200302020-00005"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr088"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/680737"},{"key":"e_1_3_5_62_2","unstructured":"Ministero della Salute. Remuneration for acute hospital care rehabilitation and long-term post-acute hospital care and specialist outpatient care: DRG 302. 2012. Available from: https:\/\/www.gazzettaufficiale.it\/eli\/gu\/2013\/01\/28\/23\/so\/8\/sg\/pdf [Last accessed: May3 2023]."},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2014.09.146"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.3111\/13696990903336597"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.852098"},{"key":"e_1_3_5_66_2","unstructured":"Socialstyrelsen. Klinikvikter NordDRG. 2022. Available from: https:\/\/www.socialstyrelsen.se\/statistik-och-data\/klassifikationer-och-koder\/drg\/viktlistor\/ [Last accessed: April12 2023]."},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2006.00100.x"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-015-0755-7"},{"key":"e_1_3_5_69_2","unstructured":"Ministerio de Sanidad. Specialized Care Activity Registry\u2013RAE-CMBD."},{"key":"e_1_3_5_70_2","unstructured":"Rechtsinformationsystem des Bundes. 2019. Available from: https:\/\/www.ris.bka.gv.at\/Dokumente\/LgblAuth\/LGBLA_WI_20190201_7\/Ambulatoriumsbeitraege_Anlage_amtssigniert.pdfsig [Last accessed: April14 2023]."},{"key":"e_1_3_5_71_2","unstructured":"Nomenclatore tariffario di specialistica ambulatoriale dgr 2989 del 23\/12\/2014 Regione Lombardia. 2014. Available from: https:\/\/www.asst-pavia.it\/sites\/default\/files\/amministrazionetrasparente\/REGOLE%20DI%20SISTEMA%202015%20dgr%202989%2023.12.2014.pdf [Last accessed: February19 2023]."},{"key":"e_1_3_5_72_2","unstructured":"\u2018eSalud.Informaci\u00f3n econ\u00f3mica del sec-tor sanitario. 2022. Available from: https:\/\/www.oblikue.com\/bddcostes\/ [Last accessed: February19 2023]."},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1275651"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.08.1481"},{"key":"e_1_3_5_75_2","unstructured":"Deloitte Access Economics. The Cost and burden of eye diseases and preventable blindness. Sydney Deloitte; 2013."},{"key":"e_1_3_5_76_2","unstructured":"\u2018Esvision.es. Informe sobre la ceguera en Espa\u00f1a; 2022 [online]. Available from: https:\/\/www.esvision.es\/wp-content\/uploads\/2019\/11\/Informe_Ceguera.pdf [Last accessed: February19 2023]."},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-009-0166-1"},{"key":"e_1_3_5_78_2","unstructured":"Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket. Prices and decisions database. 2022. Available from: https:\/\/www.tlv.se\/beslut\/sok-i-databasen.html [Last accessed: April12 2023]."},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1177\/1534734620903239"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-019-01138-y"},{"key":"e_1_3_5_81_2","unstructured":"Ministero della Salute. Remuneration for acute hospital care rehabilitation and long-term post-acute hospital care and specialist outpatient care: DRG 113. 2012. Available from: https:\/\/www.gazzettaufficiale.it\/eli\/gu\/2013\/01\/28\/23\/so\/8\/sg\/pdf [Last accessed: May3 2023]."},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-1089-6"},{"key":"e_1_3_5_83_2","unstructured":"Italian Ministry of Health. Prime Ministerial Decree 12 January 2017: The Nomenclature of Prosthetic Assistance. Available from: https:\/\/www.salute.gov.it\/portale\/temi\/p2_6.jsp?id=1312&area=programmazioneSanitariaLea&menu=lea [Last accessed: February19 2023]."},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200119070-00005"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2023.0297","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2023.0297","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2023.0297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:13:44Z","timestamp":1777400024000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2023.0297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":83,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1089\/dia.2023.0297"],"URL":"https:\/\/doi.org\/10.1089\/dia.2023.0297","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]}}}